Clinical Trials Directory

Trials / Conditions / Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

12 registered clinical trials studyying Advanced Refractory Solid Tumors — 3 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingCetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
NCT07327411
Second Affiliated Hospital of Soochow UniversityPhase 2
RecruitingStudy to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
NCT03863145
Cosmo Technologies LtdEARLY_Phase 1
UnknownHypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Adv
NCT04892498
Second Affiliated Hospital of Soochow UniversityPhase 2
RecruitingSelinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer
NCT05035745
National University Hospital, SingaporePhase 1 / Phase 2
Active Not RecruitingSafety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
NCT04685473
Taivex Therapeutics CorporationPhase 1
CompletedA Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
NCT04200404
CStone PharmaceuticalsPhase 1 / Phase 2
CompletedClinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
NCT04324372
Sunshine Lake Pharma Co., Ltd.Phase 1
TerminatedSafety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
NCT03195764
Taivex Therapeutics CorporationPhase 1
CompletedAn Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
NCT03349073
Taivex Therapeutics CorporationPhase 1
UnknownNOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
NCT02300467
National OncoVenturePhase 1
SuspendedClinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
NCT01779336
Piramal Enterprises LimitedPhase 1
SuspendedClinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
NCT01762410
Piramal Enterprises LimitedPhase 1